Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ronacaleret + plerixafor
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Ronacaleret + plerixafor is an investigational combination therapy that was evaluated for hematopoietic stem cell (HSC) mobilization. Ronacaleret (SB-751689) is a small molecule calcium-sensing receptor (CaSR) antagonist developed by GSK, while plerixafor is an approved small molecule CXCR4 antagonist. The combination was studied in a Phase I clinical trial (Study CR9116610) to determine if ronacaleret's ability to stimulate parathyroid hormone (PTH) release and activate bone metabolism could synergistically enhance the mobilization of CD34+ hematopoietic stem cells into peripheral blood when used alongside plerixafor. In the study, healthy volunteers received oral ronacaleret for five days followed by a single subcutaneous dose of plerixafor. However, the trial demonstrated no statistical difference in CD34+ cell mobilization compared to placebo plus plerixafor, leading to the discontinuation of this combination's development for stem cell mobilization.
- Other names
- SB-751689 + plerixafor
02
Targets
CXCR7 (CXC chemokine receptor 7)CaSR (Extracellular calcium-sensing receptor)CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on ronacaleret + plerixafor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ronacaleret + plerixafor.